Metabolic syndrome is a cluster of conditions — high blood pressure, high blood sugar, excess belly fat, and abnormal cholesterol — that together raise the risk of heart disease, stroke, and type 2 diabetes. About one in three American adults has it. Treatment focuses on weight loss, exercise, and managing each component individually with medications like statins and blood pressure drugs.
What's actually going on in research
Trials are testing GLP-1 receptor agonists like semaglutide for weight loss and cardiovascular protection, SGLT2 inhibitors for metabolic and kidney benefits, and combination approaches targeting multiple pathways at once. Researchers are studying how inflammation, gut bacteria, and fat tissue biology drive metabolic syndrome, and whether targeting these mechanisms can prevent progression to diabetes and heart disease.
GLP-1 receptor agonists
Drugs like semaglutide and tirzepatide produce substantial weight loss and reduce cardiovascular events in people with obesity. Trials are testing whether they can reverse metabolic syndrome before diabetes develops.
Inflammation targeting
Studies are testing whether drugs that reduce inflammation can improve insulin resistance and prevent heart disease. This includes anti-inflammatory drugs and treatments targeting specific immune pathways.
Microbiome interventions
Researchers are studying whether probiotics, prebiotics, or fecal transplants can change gut bacteria in ways that improve metabolism. Early trials suggest gut bacteria influence how the body processes sugar and fat.
What to know before you search
Eligibility typically requires meeting at least three criteria for metabolic syndrome: waist circumference, blood pressure, triglycerides, HDL cholesterol, and fasting glucose thresholds.
What types of trials are currently open
- Weight loss trials — Testing medications, behavioral programs, or combinations to produce sustained weight loss and improve metabolic markers.
- Prevention trials — Testing whether interventions in people with metabolic syndrome can prevent progression to type 2 diabetes or cardiovascular disease.
- Cardiovascular outcome trials — Large studies following people for years to see if treatments reduce heart attacks, strokes, and death.
- Mechanistic studies — Detailed studies of how treatments affect fat tissue, liver metabolism, inflammation, and insulin sensitivity.
- Lifestyle intervention trials — Testing structured diet and exercise programs, often comparing them to medication or studying how to sustain behavior change.
Recently added Metabolic Syndrome trials
Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia
Finding effective ways to slow down or prevent the development of cancer in people with Fanconi anemia (FA) is a critical medical priority. Individuals with FA are at dramatically higher risk of developing aggressive cancers, particularly of the head and neck, and these cancers are difficult to treat with standard therapies such as surgery, chemotherapy or radiation. Because options for treatment are limited and outcomes are often poor, prevention strategies are urgently needed. In this study, the investigators will test two widely available drugs, metformin and naproxen, to evaluate whether they can lower the risk of cancer in FA patients. Metformin is commonly prescribed for type 2 diabetes, while naproxen is a nonsteroidal anti-inflammatory drug (NSAID) frequently used for pain and inflammation. Both have shown potential in previous research to influence biological pathways linked to cancer development. By repurposing these well-known drugs, this trial aims to explore a safe, practical approach to cancer prevention in this vulnerable population. The study, conducted at the Rockefeller University and the University of Minnesota, has several goals. First, the investigators will carefully assess the safety and tolerability of metformin and naproxen when used in participants with FA. Because these individuals can be more susceptible to metabolic disorders like diabetes compared to the general population, and may have genitourinary abnormalities related to their underlying condition, monitoring for side effects and adverse events is especially important. Second, investigators will evaluate whether intervention affects visible or microscopic changes in the mouth, where cancers often arise. This will involve performing small biopsies of oral tissue to look for cancerous or pre-cancerous lesions. Third, investigators will investigate early molecular changes using an exploratory less invasive technique: collecting cells with a soft brush, similar to a toothbrush. These samples will allow the investigators to analyze biomarkers-biological signals that can indicate increased or reduced cancer risk-before and after intervention. Together, these approaches will provide information on whether metformin or naproxen are safe and well-tolerated in the FA population. As an additional outcome, by combining direct tissue analysis with biomarker studies, the investigators aim to detect subtle changes that precede cancer, giving us an early indication of whether the drugs are working as preventive agents. Although this is an early-phase study, its potential significance is considerable. Demonstrating that well-tolerated, inexpensive, and widely accessible drugs may have potential to reduce cancer risk would represent a major advance for FA patients, who currently face limited options for prevention and treatment. This work may also offer insights relevant to broader cancer prevention efforts in other high-risk groups. Ultimately, our study seeks to take an important step toward changing the outlook for people with Fanconi anemia by moving the focus from late-stage treatment toward early prevention.
Effect of Resistance Exercises on Serum IGF-1 Levels in Knee Osteoarthritis
The goal of this clinical trial is to evaluate the effects of a resistance exercise program on serum Insulin-like Growth Factor 1 (IGF-1) levels in patients with knee osteoarthritis. Specifically, it aims to investigate the relationship between changes in serum IGF-1 levels and clinical improvement after exercise therapy, and to evaluate the impact of the presence of osteoarthritis metabolic phenotype on this relationship. Participants will be asked to complete a structured resistance exercise program for 8 weeks. Researchers will compare the pre-exercise and post-exercise serum IGF-1 levels, clinical scores (WOMAC, VAS) and radiological findings (MOAKS Osteophyte Score) to determine the effectiveness of the intervention.
Find Metabolic Syndrome trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.